他克莫司治疗接受血液透析的类风湿关节炎患者的疗效与安全性。
Efficacy and safety of tacrolimus treatment for rheumatoid arthritis patients undergoing hemodialysis.
作者信息
Yamashita Misuzu, Natsumeda Masamitsu, Takasugi Koji, Ueno Akiko, Ezawa Kayo, Ezawa Kazuhiko
机构信息
Department of Medicine, Kurashiki Kosai Hospital, 5-4-16 Higashiduka, Kurashiki, Okayama, Japan.
出版信息
Mod Rheumatol. 2008;18(3):296-300. doi: 10.1007/s10165-008-0044-1. Epub 2008 Mar 6.
Rheumatoid arthritis (RA) is an autoimmune disorder characterized by progressive joint destruction that requires aggressive treatment using appropriate disease-modifying antirheumatic drugs (DMARDs). RA patients with renal failure, however, are intolerant to most DMARDs due to the potential toxicity. In Japan, tacrolimus was approved for the treatment of RA in 2005. Based on its pharmacokinetics, tacrolimus may be administered to the patients undergoing hemodialysis. We report two cases of RA patients on hemodialysis treated effectively and safely with tacrolimus.
类风湿关节炎（RA）是一种自身免疫性疾病，其特征为进行性关节破坏，需要使用适当的改善病情抗风湿药（DMARDs）进行积极治疗。然而，肾衰竭的RA患者由于潜在毒性，对大多数DMARDs不耐受。在日本，他克莫司于2005年被批准用于治疗RA。基于其药代动力学，他克莫司可用于接受血液透析的患者。我们报告了两例接受血液透析的RA患者使用他克莫司有效且安全治疗的病例。
Zotero 插件